Correction: Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice

Sylvia Grunewaldäll, Maria Stecklum†, Manuel Rizzo1, Jonathan Rathjens4, Lukas Fiebig1 and Dieter Zopf1,2*

Correction: European Journal of Medical Research (2023) 28:147
https://doi.org/10.1186/s40001-023-01099-2

In the original publication of the article, the order of affiliations was incorrect. The corrected order of affiliations is given in this Correction article. The abbreviations “conc Concentration” and “Y Tyrosine” were included inadvertently though they are not abbreviated in text. The abbreviations of Concentration and Tyrosine were removed. The original article has been corrected.

Published online: 24 June 2023

1†Sylvia Grunewald and Maria Stecklum contributed equally to this work.

The original article can be found online at https://doi.org/10.1186/s40001-023-01099-2.

*Correspondence:
Dieter Zopf
dieter.zopf@nuvisan.com
1 Bayer AG, Berlin, Germany
2 Present Address: Nuvisan ICB GmbH, Berlin, Germany
3 EPO Berlin-Buch GmbH, Berlin, Germany
4 Chrestos Concept GmbH & Co. KG, Essen, Germany

Reference

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.